DIETFITS Study (Diet Intervention Examining the Factors Interacting With Treatment Success

Sponsor
Stanford University (Other)
Overall Status
Completed
CT.gov ID
NCT01826591
Collaborator
Nutrition Science Initiative (Other), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (NIH), National Heart, Lung, and Blood Institute (NHLBI) (NIH)
609
1
2
40
15.2

Study Details

Study Description

Brief Summary

Genomics research is advancing rapidly, and links between genes and obesity continue to be discovered and better defined. A growing number of single nucleotide polymorphisms (SNPs) in multiple genes have been shown to alter an individual's response to dietary macronutrient composition. Based on prior genetic studies evaluating the body's physiological responses to dietary carbohydrates or fats, the investigators identified multi-locus genotype patterns with SNPs from three genes (FABP2, PPARG, and ADRB2): a low carbohydrate-responsive genotype (LCG) and a low fat-responsive genotype (LFG). In a preliminary, retrospective study (using the A TO Z weight loss study data), the investigators observed a 3-fold difference in 12-month weight loss for initially overweight women who were determined to have been appropriately matched vs. mismatched to a low carbohydrate (Low Carb) or low fat (Low Fat) diet based on their multi-locus genotype pattern. The primary objective of this study is to confirm and expand on the preliminary results and determine if weight loss success can be increased if the dietary approach (Low Carb vs. Low Fat) is appropriately matched to an individual' s genetic predisposition (Low Carb Genotype vs. Low Fat Genotype) toward those diets.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Low-Carbohydrate Diet
  • Behavioral: Low-Fat Diet
  • Behavioral: Mobile App
N/A

Detailed Description

If the intriguing preliminary retrospective results are confirmed in this full scale study, the results will demonstrate that inexpensive DNA testing could help dieters predict whether they will have greater weight loss success on a Low Carb or a Low Fat diet. Commensurate with increasing scientific interest in personalized medicine approaches to intervention development, this would provide an example of the potentially substantial health impacts that could be obtained through understanding specific gene-environment interactions that have been anticipated from the unraveling of the human genome.

Mobile App Sub-Study-For the purpose of augmenting adherence to high vegetable consumption in both diet groups, we will develop a theory-based mobile app to increase vegetable consumption through goal-setting, self-monitoring, and social comparison. Participants from both diet groups with iPhones will be re-randomized to receive the app at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet arms. The investigator and outcomes assessor will be blinded to group assignment. Intention-to-treat analysis will be used.

Study Design

Study Type:
Interventional
Actual Enrollment :
609 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Do Insulin Secretion or Genotype Pattern Predict Low Fat vs Low Carb Weight Loss Success?
Actual Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
May 1, 2016
Actual Study Completion Date :
May 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental: Low-Carbohydrate Diet

Healthy, Low-Carbohydrate Diet

Behavioral: Low-Carbohydrate Diet
Counseling/instruction on how to follow a low-carbohydrate diet.

Behavioral: Mobile App
Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.

Experimental: Experimental: Low-Fat Diet

Healthy, Low-Fat Diet

Behavioral: Low-Fat Diet
Counseling/instruction on how to follow a low-fat diet.

Behavioral: Mobile App
Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline in weight at 12 months [Baseline and 12 months]

    Weight change was calculated as the 12 month value minus the baseline value. The study was designed to determine if either insulin secretion or genotype pattern (low-fat genotype pattern vs .low-carb genotype pattern) were significant effect modifiers of 12-month weight loss for the two diet arms (e.g., 2X2 analyses).

Secondary Outcome Measures

  1. Change from baseline in LDL cholesterol at 12 months [Baseline and 12 months]

    LDL-cholesterol change was calculated as the 12 month value minus the baseline value.

  2. Change from baseline in HDL cholesterol at 12 months [Baseline and 12 months]

    HDL-cholesterol change was calculated as the 12 month value minus the baseline value.

  3. Change from baseline in triglycerides at 12 months [Baseline and 12 months]

    Triglycerides change was calculated as the 12 month value minus the baseline value.

  4. Change from baseline in fasting insulin at 12 months [Baseline and 12 months]

    Fasting insulin change was calculated as the 12 month value minus the baseline value.

  5. Change from baseline in fasting glucose at 12 months [Baseline and 12 months]

    Fasting glucose change was calculated as the 12 month value minus the baseline value.

  6. Change from baseline in insulin after an oral-glucose tolerance test (OGTT) at 12 months [Baseline and 12 months]

    Post-OGTT insulin change was calculated as the 12 month value minus the baseline value.

  7. Change from baseline in glucose after an oral-glucose tolerance test (OGTT) at 12 months [Baseline and 12 months]

    Post-OGTT glucose change was calculated as the 12 month value minus the baseline value.

  8. Change from baseline in body fat percentage at 12 months. [Baseline and 12 months]

    Body fat percentage was assessed by dual-energy x-ray absorptiometry (DXA) and the change was calculated as the 12 month value minus the baseline value.

  9. Change from baseline in body mass index (BMI) at 12 months. [Baseline and 12 months]

    BMI change was calculated as the 12 month value minus the baseline value.

  10. Change from baseline in resting energy expenditure (REE) at 12 months. [Baseline and 12 months]

    REE was assessed by indirect calorimetry and the change was calculated as the 12 month value minus the baseline value.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age: > 18 years of age

  • Women: Pre-menopausal (self-report) and <50 years of age

  • Men: <50 years of age

  • BMI (body mass index): 27-40 kg/m2 (need to lose >10% body weight to achieve healthy BMI)

  • Body weight stable for the last two months, and not actively on a weight loss plan

  • No plans to move from the area over the next two years

  • Available and able to participate in the evaluations and intervention for the study period

  • Willing to accept random assignment

  • To enhance study generalizability, people on medications not noted below as specific exclusions can

  • participate if they have been stable on such medications for at least three months

  • Ability and willingness to give written informed

  • No known active psychiatric illness

Exclusion Criteria:
Subjects with the following conditions will be excluded (determined by self-report):
  • Pregnant, lactating, within 6 months post-partum, or planning to become pregnant in the next 2 years

  • Diabetes (type 1 and 2) or history of gestational diabetes or on hypoglycemic medications for any other indication

  • Prevalent diseases: Malabsorption, renal or liver disease, active neoplasms, recent myocardial infarction (<6 months)(patient self-report and, if available, review of labs from primary care provider)

  • Smokers (because of effect on weight and lipids)

  • History of serious arrhythmias, or cerebrovascular disease

  • Uncontrolled hyper- or hypothyroidism (TSH not within normal limits)

  • Medications: Lipid lowering, antihypertensive medications, and those known to affect weight/energy expenditure

  • Excessive alcohol intake (self-reported, >3 drinks/day)

  • Musculoskeletal disorders precluding regular physical activity

  • Unable to follow either of the two study diets for reasons of food allergies or other (e.g., vegan)

  • Currently under psychiatric care, or taking psychiatric medications

  • Inability to communicate effectively with study personnel

Contacts and Locations

Locations

Site City State Country Postal Code
1 Stanford University School of Medicine Stanford California United States 94305

Sponsors and Collaborators

  • Stanford University
  • Nutrition Science Initiative
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Principal Investigator: Christopher D Gardner, PhD, Stanford University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Christopher Gardner, Professor of Medicine, Stanford University
ClinicalTrials.gov Identifier:
NCT01826591
Other Study ID Numbers:
  • 22305
  • 1R01DK091831
  • T32HL007034
  • UL1TR001085
First Posted:
Apr 8, 2013
Last Update Posted:
Aug 10, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 10, 2020